Charles Muller1, Sang Mee Lee1, William Barge2, Shazia M Siddique3, Shivali Berera4, Gina Wideroff4, Rashmi Tondon3, Jeremy Chang1, Meaghan Peterson1, Jessica Stoll1, Bryson W Katona3, Daniel A Sussman4, Joshua Melson2, Sonia S Kupfer5. 1. Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois. 2. Division of Digestive Diseases and Nutrition, Rush University, Chicago, Illinois. 3. Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Gastroenterology Division, University of Miami, Miami, Florida. 5. Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois. Electronic address: skupfer@medicine.bsd.uchicago.edu.
Abstract
BACKGROUND & AIMS: Guidelines recommend that all colorectal tumors be assessed for mismatch repair deficiency, which could increase identification of patients with Lynch syndrome. This is of particular importance for minority populations, in whom hereditary syndromes are under diagnosed. We compared rates and outcomes of testing all tumor samples (universal testing) collected from a racially and ethnically diverse population for features of Lynch syndrome. METHODS: We performed a retrospective analysis of colorectal tumors tested from 2012 through 2016 at 4 academic centers. Tumor samples were collected from 767 patients with colorectal cancer (52% non-Hispanic white [NHW], 26% African American, and 17% Hispanic patients). We assessed rates of tumor testing, recommendations for genetic evaluation, rates of attending a genetic evaluation, and performance of germline testing overall and by race/ethnicity. We performed univariate and multivariate regression analyses. RESULTS: Overall, 92% of colorectal tumors were analyzed for mismatch repair deficiency without significant differences among races/ethnicities. However, minority patients were significantly less likely to be referred for genetic evaluation (21.2% for NHW patients vs 16.9% for African American patients and 10.9% for Hispanic patients; P = .02). Rates of genetic testing were also lower among minority patients (10.7% for NHW patients vs 6.0% for AA patients and 3.1% for Hispanic patients; P < .01). On multivariate analysis, African American race, older age, and medical center were independently associated with lack of referral for genetic evaluation and genetic testing. CONCLUSION: In a retrospective analysis, we found that despite similar rates of colorectal tumor analysis, minority patients are less likely to be recommended for genetic evaluation or to undergo germline testing for Lynch syndrome. Improvements in institutional practices in follow up after tumor testing could reduce barriers to diagnosis of Lynch diagnosis in minorities.
BACKGROUND & AIMS: Guidelines recommend that all colorectal tumors be assessed for mismatch repair deficiency, which could increase identification of patients with Lynch syndrome. This is of particular importance for minority populations, in whom hereditary syndromes are under diagnosed. We compared rates and outcomes of testing all tumor samples (universal testing) collected from a racially and ethnically diverse population for features of Lynch syndrome. METHODS: We performed a retrospective analysis of colorectal tumors tested from 2012 through 2016 at 4 academic centers. Tumor samples were collected from 767 patients with colorectal cancer (52% non-Hispanic white [NHW], 26% African American, and 17% Hispanic patients). We assessed rates of tumor testing, recommendations for genetic evaluation, rates of attending a genetic evaluation, and performance of germline testing overall and by race/ethnicity. We performed univariate and multivariate regression analyses. RESULTS: Overall, 92% of colorectal tumors were analyzed for mismatch repair deficiency without significant differences among races/ethnicities. However, minority patients were significantly less likely to be referred for genetic evaluation (21.2% for NHW patients vs 16.9% for African American patients and 10.9% for Hispanic patients; P = .02). Rates of genetic testing were also lower among minority patients (10.7% for NHW patients vs 6.0% for AA patients and 3.1% for Hispanic patients; P < .01). On multivariate analysis, African American race, older age, and medical center were independently associated with lack of referral for genetic evaluation and genetic testing. CONCLUSION: In a retrospective analysis, we found that despite similar rates of colorectal tumor analysis, minority patients are less likely to be recommended for genetic evaluation or to undergo germline testing for Lynch syndrome. Improvements in institutional practices in follow up after tumor testing could reduce barriers to diagnosis of Lynch diagnosis in minorities.
Authors: Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter Journal: J Genet Couns Date: 2011-12-14 Impact factor: 2.537
Authors: Reshma Jagsi; Kent A Griffith; Allison W Kurian; Monica Morrow; Ann S Hamilton; John J Graff; Steven J Katz; Sarah T Hawley Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: Sonia S Kupfer; Andrew D Skol; Ellie Hong; Anton Ludvik; Rick A Kittles; Temitope O Keku; Robert S Sandler; Nathan A Ellis Journal: Carcinogenesis Date: 2014-04-21 Impact factor: 4.944
Authors: Laura C Beamer; Marcia L Grant; Carin R Espenschied; Kathleen R Blazer; Heather L Hampel; Jeffrey N Weitzel; Deborah J MacDonald Journal: J Clin Oncol Date: 2012-02-21 Impact factor: 44.544
Authors: Elena Stoffel; Bhramar Mukherjee; Victoria M Raymond; Nabihah Tayob; Fay Kastrinos; Jennifer Sparr; Fei Wang; Prathap Bandipalliam; Sapna Syngal; Stephen B Gruber Journal: Gastroenterology Date: 2009-07-18 Impact factor: 22.682
Authors: Julian A Sanchez; Jon D Vogel; Matthew F Kalady; Mary P Bronner; Marek Skacel; James M Church Journal: Dis Colon Rectum Date: 2008-08-06 Impact factor: 4.585
Authors: Kristen S Purrington; Ann G Schwartz; Julie J Ruterbusch; Mark A Manning; Mrudula Nair; Angela S Wenzlaff; Stephanie S Pandolfi; Michael S Simon; Jennifer Beebe-Dimmer Journal: Cancer Date: 2020-08-04 Impact factor: 6.860
Authors: Jessica E Ebrahimzadeh; Jessica M Long; Louise Wang; John T Nathanson; Shazia Mehmood Siddique; Anil K Rustgi; David S Goldberg; Bryson W Katona Journal: J Genet Couns Date: 2020-03-30 Impact factor: 2.537
Authors: Marilyn Huang; Tegan Hunter; Lydia A Fein; Johnny Galli; Sophia George; Matthew Schlumbrecht; Kelly McCarter; Abdulrahman K Sinno; Luiz P Guido; Andre Pinto Journal: Sci Rep Date: 2021-06-03 Impact factor: 4.379